

Supporting Information

Metallo- β -lactamase inhibitor phosphoramidate monoesters

Katarzyna Palica,[†] Manuela Voráčová,[†] Susann Skagseth,[‡] Anna Andersson Rasmussen,[†] Lisa Allander,[±] Madlen Hubert,[‡] Linus Sandegren,[±] Hanna-Kirsti Schröder Leiros,[‡] Hanna Andersson,^{*,†} and Máté Erdélyi^{*,†}

[†] Department of Chemistry - BMC, Organic Chemistry; Uppsala University, Husargatan 3, 752 37 Uppsala, Sweden

[‡] The Norwegian Structural Biology Centre (NorStruct), Department of Chemistry, Faculty of Science and Technology, UiT The Arctic University of Norway, N-9037 Tromsø, Norway

[±] Department of Medical Biochemistry and Microbiology – BMC, Uppsala University, Husargatan 3, 752 37 Uppsala, Sweden

[‡] Department of Pharmacy – BMC, Uppsala University, Husargatan 3, 752 37 Uppsala, Sweden

Table of contents


1. Dose-response graphs.....	3
3. MIC studies for NDM-1	6
4. Cytotoxicity assay	7
5. NMR assignment of NDM-1, chemical shift titration and NOE	8
6. The protein sequence of NDM-1	15
7. NMR spectra of the synthesized compounds	19


The protein NMR data has been deposited to the Biological Magnetic Resonance Bank with BMRB ID 50945. The original NMR FIDs for all compounds are available free of charge on Zenodo as DOI:10.5281/zenodo.4773990.

1. Dose-response graphs

Table S1. The dose-response graphs.

Inhibitors	NDM-1	GIM-1	VIM-2
1a	<p>191113 NDM-1 KAT-A-142-H2</p>	<p>KAT-A-142-H1 GIM-1</p> <p>IC₅₀ = 86 μM</p>	<p>191031 VIM-2 KAT-A-142-H2</p>
1b	<p>KAT-A-139-H1 NDM-1</p> <p>IC₅₀ = 356 μM</p>	<p>KAT-A-139-H1 GIM-1</p> <p>IC₅₀ = 109 μM</p>	<p>KAT-A-139-H1 VIM-2</p> <p>IC₅₀ = >1400 μM</p>





3. MIC studies for NDM-1

Table S2. Susceptibility assay with *E. coli* ATCC 25922 NDM-1

Compound	Minimum inhibitory concentration (mg/L)		
	Meropenem:compound ratio		Meropenem
No compound			32
EDTA 100 μ M			< 2
1c	8:1024	4:1024	2:1024
1b	8:1024	4:1024	2:1024
1d	8:1024	4:1024	> 2:1024
1a	8:1024	4:1024	2:1024
1h	8:1024	4:1024	2:1024

***1e**, **1g** and **1f** could not be dissolved in MIC assay.

4. Cytotoxicity assay




Figure S1. Cytotoxicity dose-response curves of phosphoramidate monoesters as determined in HeLa cells. The cells were treated with the compounds at the indicated concentrations, and cell viability was measured after 24 hours incubation. The following IC₅₀ values were determined to be (A) 69.2 μM (SD = 1.0) for KAT-A-109-H2, (B) 201.4 μM (SD = 4.4) for KAT-A-102-H1 and (C) 90.7 μM (SD = 1.0) for KAT-A-118-H1. All remaining compounds (D-H) had IC₅₀ values above 500 μM. Data is shown as mean ± SD of at least two independent experiments.

*A **1h**, B **1e**, C **1f**, D **1a**, E **1b**, F **1d**, G **1c**.

5. NMR assignment of NDM-1, chemical shift titration and NOE




Figure S2. Expansion of the overlapping area of ^1H , ^{15}N HSQC with assignment of chemical shift of NDM-1




Figure S3. Superposition of the full ^1H , ^{15}N HSQC spectrum of free NDM-1 (titration step 0 in red), and NDM-1 bound to **1d** (last step 10 eq blue)




Figure S4. ^1H , ^{15}N HSQC of NDM-1 (green) with 5% EtOH (red).




Figure S5. ^1H - ^{15}N HSQC of NDM-1 (red) with 5% DMSO (green).




Figure S6. 2D ^{15}N -filtered NOESY for NDM-1 with **1d** (8 eq).




Figure S7. 3D ^{15}N -filtred HSQC-NOESY in 3D cube mode for NDM-1 and **1d** (8eq). Dimensions: F1 = chemical shift of ^{15}N protein; F2 = chemical shift of ^1H protein, F3 = chemical shift of ^1H ligand.




Figure S8. Highlighted green and pink amino acid residues on the NDM-1 (*PDB:4exs*) secondary structure with SSP corresponding to weighted average ($^1\text{H}, ^{15}\text{N } \Delta\delta$) greater than the population mean plus standard deviation ($\mu+1\sigma$). Pink colored residues are highlighted due to additional NOE correlations detected in the 3D ^{15}N -filtered HSQC-NOESY.

6. The protein sequence of NDM-1

Figure S9. Sequence of pET27b(+)_His-NDM-1

LacI

LacI promoter

T7 promoter

Lac operator

Ribosome binding site

PelB sequence

NDM-1 gene

TEV site encoding bases

His-tag

```
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTA
CGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCCTCCTTTTCGCTTTCTT
CCCTTCCTTTCTCGCCACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTC
CCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAG
GGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACG
TTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACAACACTCAAC
CCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTT
AAAAAATGAGCTGATTTAACAAAAATTTAACCGGAATTTAACAAAATATTAACGTT
TACAATTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTT
TTCTAAATACATTCAAATATGTATCCGCTCATGAATTAATTCTTAGAAAACTCATC
GAGCATCAAATGAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTG
AAAAGCCGTTTCTGTAATGAAGGAGAAAACCTACCGAGGCAGTTCCATAGGATGG
CAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTA
ATTTCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTG
AATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCC
AGCCATTACGCTCGTCATCAAATCACTCGCATCAACCAAACCGTTATTCATTCGTG
ATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACA
GGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACC
TGAATCAGGATATTCTTCTAATACTGGAATGCTGTTTTCCCGGGGATCGCAGTGGT
GAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCA
TAAATTCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCT
ACCTTTGCCATGTTTCAGAAACAACACTCTGGCGCATCGGGCTTCCCATAACAATCGATA
GATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCATTTATACCCATATAAATC
AGCATCCATGTTGGAATTTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATG
GCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTTCATGAC
```

CAAAATCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGAT
CAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAA
AAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACCAACTCTTTTT
CCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTG
CTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTG
GACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTC
GTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCG
GTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACG
CCTGGTATCTTTATAGTCCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTT
GTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAACGCCAGCAACGCGGCCTTTT
TACGGTTCCTGGCCTTTTGTGCTGGCCTTTTGTCTACATGTTCTTTCCTGCGTTATCCCCT
GATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGC
CGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGC
GGTATTTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATATGGTGCACCTCTC
AGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACTCCGCTATCGCTAC
GTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGA
CGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGC
TGCATGTGTCAGAGGTTTTACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAA
AGCTCATCAGCGTGGTCGTGAAGCGATTACAGATGTCTGCCTGTTTATCCGCGTCC
AGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATG
TTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGT
TCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACT
GATGATGAACATGCCCGTTACTGGAACGTTGTGAGGGTAAACAACCTGGCGGTATG
GATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATA
CAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAAC
ATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCG
AAGACCATTGATGTTGTTGCTCAGGTCGCAGACGTTTTTGCAGCAGCAGTCGCTTAC
GTTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCT
AGCCGGGTCTCAACGACAGGAGCAGATCATGCGCACCCGTGGGGCCGCCATGCC
GGCGATAATGGCCTGCTTCTCGCCGAAACGTTTTGGTGGCGGGACCAGTGACGAAGG
CTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTC
GCGCTCCAGCGAAAGCGGTCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTG
TCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGGCAGCAGATAGTCATGC
CCC GCGCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTGCA
GATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCC
GCTTTCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCG
GGGAGAGGCGGTTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTACCAGTGAGAC
GGGCAACAGCTGATTGCCCTTACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGT
CCACGCTGGTTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGA
TATAACATGAGCTGTCTTCGGTATCGTCGTATCCC ACTACCGAGATATCCGCACCAA
CGCGCAGCCCGACTCGGTAATGGCGCGCATTGCGCCAGCGCCATCTGATCGTTGG
CAACCAGCATCGCAGTGGGAACGATGCCCTCATTGAGCATTGTCATGGTTTTGTTGAA
AACCGGACATGGCACTCCAGTCGCCTTCCC GTTCCGCTATCGGCTGAATTTGATTGC
GAGTGAGATATTTATGCCAGCCAGCCAGACGCGAGACGCGCCGAGACAGAACTAAT

GGGCCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCC
CAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGA
GACATCAAGAAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCAT
CCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGAT
TGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCA
CGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGC
GCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGC
CAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCAC
TTTTCCCGCGTTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAACGGT
CTGATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTACATT
CACCACCCTGAATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTT
GCGCCATTTCGATGGTGTCCGGGATCTCGACGCTCTCCCTTATGCGACTCCTGCATTA
GGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGT
GCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCATAACC
CACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGG
TGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCC
ACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTC
ACTATAGGGGAATTGTGAGCGGATAACAATTCCCTCTAGAAATAATTTTGTTTAAC
TTAAGAGGAGATATACATATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGC
TGCTCCTCGCTGCCAGCCGGCGATGGCCATGgctgcaaccatcatcatcatcttctggttagatctgg
gtaccgagaacctgtaactccaaggCAGCAAATGGAACTGGCGACCAACGGTTTGGCGATCTGG
TTTTCCGCCAGCTCGCACCGAATGTCTGGCAGCACACTTCCTATCTCGACATGCCGG
GTTTCGGGGCAGTCGCTTCCAACGGTTTGATCGTCAGGGATGGCGGCCGCGTGCTGG
TGGTCGATACCGCCTGGACCGATGACCAGACCGCCAGATCCTCAACTGGATCAAG
CAGGAGATCAACCTGCCGGTCGCGCTGGCGGTGGTGACTCACGCGCATCAGGACAA
GATGGGCGGTATGGACGCGCTGCATGCGGCGGGGATTGCGACTTATGCCAATGCGT
TGTCGAACCAGCTTGCCCCGCAAGAGGGGATGGTTGCGGCGCAACACAGCCTGACT
TTCGCCGCCAATGGCTGGGTGGAACCAGCAACCGCGCCCACTTTGGCCCCGCTCAAG
GTATTTTACCCCGGCCCGGCCACACCAGTGACAATATCACCGTTGGGATCGACGGC
ACCGACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAGGCCAAGTCGCTCGG
CAATCTCGGTGATGCCGACACTGAGCACTACGCCGCGTCAGCGCGCGCTTTGGTGC
GGCGTTCCCAAGGCCAGCATGATCGTGATGAGCCATTCGCCCCCGATAGCCGCGC
CGCAATCACTCATACGGCCCGCATGGCCGACAAGCTGCGCTAATGAGGATCCGAAT
TCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGATCAAACGGGCTAGCCAGCC
AGAACTCGCCCCGGAAGACCCCGAGGATGTCGAGCACCACCACCACCACCTGAG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAG
CAATAACTAGCATAAACCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTG
AAAGGAGGAACTATATCCGGAT

Figure S10. Protein sequence of the produced NDM-1 after TEV cleavage:

GQQMETGDQRFGDLVFRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTA
WTDDQTAQILNWIKEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLA
PQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPPGHTSDNITVGIDGTDIAFGGC
LIKDSKAKSLGNLGDADTEHYAASARAFGAAFP KASMIVMSHSAPDSRAAITHARMA
DKLR

7. NMR spectra of the synthesized compounds




Figure S11. ¹H NMR spectrum of 4.




Figure S12. ^{13}C NMR spectrum of **4**.




Figure S13. ^{31}P NMR spectrum of **4**.




Figure S14. ¹H NMR spectrum of **5**.




Figure S15. ^{13}C NMR spectrum of **5**.




Figure S16. ^{31}P NMR spectrum of **5**.




Figure S17. ^1H NMR spectrum of 7.




Figure S18. ^{13}C NMR spectrum of 7.




Figure S19. ^{31}P NMR spectrum of **7**.




Figure S20. ¹H NMR spectrum of **8**.




Figure S21. ¹³C NMR spectrum of **8**.




Figure S22. ^{31}P NMR spectrum of **8**.




Figure S23. ¹H NMR spectrum of **9**.




Figure S24. ¹³C NMR spectrum of **9**.




Figure S25. ^{31}P NMR spectrum of **9**.





Figure S26. ¹H NMR spectrum of **10**.






Figure S28. ^{31}P NMR spectrum of **10**.




Figure S29. ¹H NMR spectrum of **1a**.




Figure S30. ^{13}C NMR spectrum of 1a.




Figure S31. ^{31}P NMR spectrum of **1a**.




Figure S32. ¹H NMR spectrum of **1b**.




Figure S33. ¹³C NMR spectrum of **1b**.




Figure S34. ^{31}P NMR spectrum of **1b**.




Figure S35. ¹H NMR spectrum of 1c.




Figure S36. ¹³C NMR spectrum of **1c**.




Figure S37. ^{31}P NMR spectrum of **1c**.




Figure S38. ^1H NMR spectrum of **1d**.




Figure S39. ¹³C NMR spectrum of **1d**.




Figure S40. ^{31}P NMR spectrum of **1d**.



Figure S41. ^1H NMR spectrum of **1e**.




Figure S42. ^{13}C NMR spectrum of **1e**.




Figure S43. ^{31}P NMR spectrum of **1e**.




Figure S44. ¹H NMR spectrum of **1f**.




Figure S45. ^{13}C NMR spectrum of **1f**.




Figure S46. ^{31}P NMR spectrum of **1f**.




Figure S47. ¹H NMR spectrum of **1g**.




Figure S48. ¹³C NMR spectrum of **1g**.




Figure S49. ^{31}P NMR spectrum of **1g**.




Figure S50. ^1H - ^{13}C HSQC NMR spectrum of **1g**.




Figure S51. ^1H - ^{31}P HMBC NMR spectrum of **1g**.




Figure S52. ^1H NMR spectrum of **1h**.




Figure S53. ¹³C NMR spectrum of **1h**.




Figure S54. ^{31}P NMR spectrum of **1h**.